Ocugen, Inc.

Ocugen, Inc.

0.76
USD
-0.02
(-2.11%)
-0.20EPS
349.49MMarket Cap
Mar 10Next Earn

Ocugen, Inc. Documents

Q4 FY2025 · Press release

Ocugen Announces Positive Preliminary Phase 2 Data from OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration · 2 pages

Read Ocugen, Inc.'s results firsthand

Preview this press release
Create a free account to start reading

Full documents are included with Professional

Q4 FY2025 documents